GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IVERIC bio Inc (NAS:ISEE) » Definitions » EPS without NRI

IVERIC bio (IVERIC bio) EPS without NRI : $-1.76 (TTM As of Mar. 2023)


View and export this data going back to 2013. Start your Free Trial

What is IVERIC bio EPS without NRI?

IVERIC bio's earnings per share without non-recurring items for the three months ended in Mar. 2023 was $-0.53. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2023 was $-1.76.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -3.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for IVERIC bio's EPS without NRI or its related term are showing as below:

ISEE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -67.6   Med: 4.9   Max: 42.3
Current: -3.3

During the past 12 years, IVERIC bio's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 42.30% per year. The lowest was -67.60% per year. And the median was 4.90% per year.

ISEE's 3-Year EPS without NRI Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 5.5 vs ISEE: -3.30

IVERIC bio's EPS (Diluted) for the three months ended in Mar. 2023 was $-0.53. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-1.76.

IVERIC bio's EPS (Basic) for the three months ended in Mar. 2023 was $-0.53. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2023 was $-1.76.


IVERIC bio EPS without NRI Historical Data

The historical data trend for IVERIC bio's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IVERIC bio EPS without NRI Chart

IVERIC bio Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.70 -1.39 -1.14 -1.12 -1.53

IVERIC bio Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -0.41 -0.35 -0.47 -0.53

Competitive Comparison of IVERIC bio's EPS without NRI

For the Biotechnology subindustry, IVERIC bio's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IVERIC bio's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IVERIC bio's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where IVERIC bio's PE Ratio without NRI falls into.



IVERIC bio EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IVERIC bio  (NAS:ISEE) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


IVERIC bio EPS without NRI Related Terms

Thank you for viewing the detailed overview of IVERIC bio's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


IVERIC bio (IVERIC bio) Business Description

Traded in Other Exchanges
N/A
Address
8 Sylvan Way, Parsippany, New Jersey, USA, 07054
IVERIC bio Inc is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases, or IRDs.
Executives
Keith Westby officer: SVP & COO ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
David Francis Carroll officer: SVP, CFO and Treasurer ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
Glenn Sblendorio director 3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
Christopher Paul Simms officer: Senior Vice President, CCO FIVE PENN PLAZA SUITE 2372, NEW YORK NY 10001
Anthony S Gibney officer: EVP, Chief Business Officer C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Calvin W. Roberts director 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Christine Ann Miller director 5 PENN PLAZA, SUITE 2372, NEW YORK NY 10001
Pravin Dugel officer: EVP, Chief Strategy & Business C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
David R Guyer director, officer: Chief Executive Officer ONE PENN PLAZA, 19TH FLOOR, NEW YORK NY 10119
Mark S. Blumenkranz director C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111
Adrienne L Graves director 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Versant Venture Capital Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Iv, Llc 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Side Fund Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Jane Henderson director C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142